Genomeditech is excited to announce participation in the CHABS 2026 Annual Conference, hosted by the Chinese Antibody Society. The conference brings together leading researchers, biotech innovators, and pharmaceutical professionals worldwide to explore the latest progress in antibody therapeutics, biologics development, and translational medicine.
Recognized as a key industry gathering in the antibody field, the CHABS Annual Conference provides a valuable platform for scientific exchange and collaboration across discovery, engineering, and therapeutic development. Topics spanning next-generation antibody modalities, bispecific antibodies, ADCs, immune-oncology, and emerging platform technologies continue to shape discussions at the meeting and reflect the rapid evolution of the biologics landscape.
As a company focused on enabling biologics and drug discovery research, Genomeditech looks forward to connecting with industry partners and sharing its latest capabilities in stable cell line development and target validation solutions. Through continuous platform optimization and product innovation, Genomeditech remains committed to supporting researchers in accelerating therapeutic development from early-stage discovery to translational research.
We look forward to meeting colleagues and collaborators at the CHABS 2026 Annual Conference and contributing to conversations driving the next generation of antibody therapeutics and biologic innovation.
For more details about the event, please visit the official CHABS 2026 Annual Conference website: https://www.chabs.org/2026-annual-conference
Time: May 9–10, 2026
Location: Boston Marriott Cambridge | Boston, MA
